Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein A-I and B metabolism

Kidney International

Volumn 50, Issue 6, 1996, Pages 2079-2087

  Shah, Gaurang M ^b   Lin, Zuo Lun ^b   Kamanna, Vaijinath S ^b   Pai, Rama ^b   Bassa, Babu ^b   Jin, Fu You ^b   Roh, Daeyoung Dave ^b   Kashyap, Moti L ^b   Kirschenbaum, Michael A ^a  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B;

ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; HEPATOBLASTOMA; HUMAN; MALE; PRIORITY JOURNAL; SERUM SUBFRACTION;

EID: 0029902296     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.532     Document Type: Article

References (37)

1. BLOEMBERGEN WE, PORT FK, MAUGER EA, WOLFE RA: A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 6:177-183, 1995
2. BLOEMBERGEN WE, PORT FK, MAUGER EA, WOLFE RA: A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 6:184-191, 1995
3. KAYSEN GA: Hyperlipidemia of chronic renal failure. Blood Purif 12:60-67, 1994
4. ATTMAN PO, ALAUPOVIC P: Lipid and apolipoprotein profiles of uremic dyslipoproteinemia: Relation to renal function and dialysis. Nephron 57:401-410, 1991
5. HORKKO S, HUTTUNEN K, LAARA E, KERVINEN K, KESANIEMI YA: Effects of three tretment modes on plasma lipids and lipoproteins in uremic patients. Annal Med 26:271-282, 1994
6. AVRAM MM, GOLDWASSER P, BURRELL DE, ANTIGNANI A, FEIN PA, MITTMAN N: The uremic dyslipidemia: A cross sectional and longitudinal study. Am J Kidney Dis 20:324-325, 1992
7. ROSS EA, SHAH GM, KASHYAP ML: Elevated plasma lipoprotein (a) levels and hypoalbuminemia in peritoneal dialysis patients. Int J Artif Organs (in press)
8. LEVINE DM, GORDON BR: Lipoprotein (a) levels in patients receiving renal replacement therapy: Methodologic issues and clinical implications. Am J Kidney Dis 26:162-169, 1994
9. KAMMANA VS, KASHYAP ML, PAI R, BUI DT, JIN F, ROH DD, SHAH GM, KIRSCHENBAUM MA: Uremic serum subfraction inhibits apoprotein A-I production by a human hepatoma cell line. J Am Soc Nephrol 5:193-200, 1994
10. POPOVICH RP, MONCRIEF JW, PYLE WK: Transport kinetics, in Peritoneal Dialysis, edited by NOLPH KD, Basle, Kluwer, 1989, pp 96-116
11. POLLOCK CA, WYNDHAM R, COLLETT PV, EDLER G, FIELD MJ, KALOWSKI S, LAWRENCE JR, WAUGH DA, GEORGE CRP: Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. Kidney Int 45:897-902, 1994
12. LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275, 1951
13. ROTHWELL TC, KAMANNA VS, JIN F-Y, KOREN E, FOLEY T, KASHYAP ML: Characterization of a monoclonal antibody (HB-22) and development of an ELlSA for human apolipoprotein A-I. Clin Chem 41:1150-1158, 1995
14. AMARASURIYA RN, GUPTA AK, CIVEN M, HORNIG YC, MAEDA T, KASHYAP ML: Ethanol stimulates apolipoprotein A-I secretion by human hepatocytes: Implication for a mechanism for atherosclerosis protection. Metabolism 41:827-832, 1992
15. FIELDING CJ, FIELDING PE: Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase. Proc Natl Acad Sci USA 78:3911-3914, 1981
16. ROTHBLATT GH, BAMBERGER M, PHILLIPS MC: Reverse cholesterol transport, in Methods in Enzymology, edited by COLOWICK SP, KAPLAN NO, Orlando, Academic Press, 1986, pp 628-644
17. CHOMCZYNSKI P, SACCHI N: Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Chem 162:156-159, 1987
18. SAMBROOK J, FRITSCH EF, MANIATIS T: Molecular Cloning: A Laboratory Manual (2nd ed), Cold Spring Harbor, Cold Spring Harbor Press, 1489
19. BAZILINSKI N, SHAYKH M, DUNEA G, MAMDANI B, PATEL A, CZAPEK E, AHMED S: Inhibition of platelet function by uremic middle molecules. Nephrom 40:423-428, 1985
20. RHEE MS, MCGOLDRICK MD, MEUWISSEN HJ: Serum factor from patients with chronic renal failure enhances polymorphonuclear leukocyte oxidative metabolism. Nephron 42:6-13, 1986
21. FUH MT, LEE CM, JENG CY, SHEN DC, SHEIH SM, REAVEN GM, CHEN Y-D: Effect of chronic renal failure on high-density lipoprotein kinetics. Kidney Int 37:1295-1300, 1990
22. SAKU K, GARTSIDE PS, HYND BA, MENDOZA SG, KASHYAP ML: Apolipoprotein A-I and A-II metabolism in patients with primary high density lipoprotein deficiency associated with familial hypertriglyceridemia. Metabolism 34:754-764, 1985
23. DECKELBAUM RJ, GRANOT E, OSCHRY R, ROSE L, EISENBERG S: Plasma triglyceride determines structure composition in low and high density lipoproteins. Arteriosclerosis 4:225-231, 1984
24. GRUNDY SM, VEGA GL: Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Arch Intern Med 152:28-34, 1992
25. SHOJI T, NISHIZAWA Y, NISHITANI H, YAMAKAWA M, MORII H: Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 41:1653-1661, 1992
26. HORKKO S, HUTTUNEN K, KESANIEMI A: Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment. Kidney Int 47:1732-1740, 1995
27. HENKIN Y, NEEMAN Z, ZULLI, I, CHAIMOVITZ C, SHANY S: The relationship between plasma and dialysate lipoproteins and apoproteins in patients treated by continuous ambulatory peritoneal dialysis. Am J Kidney Dis 22:829-834, 1993
28. BORCHARDT RA, DAVIS RA: Intrahepatic assemby of very low desnity lipoproteins: Rate of transport out of the endoplasmic reticulum determines rate of secretion. J Biol Chem 262:16394-16402, 1987
29. SPARKS JD, SPARKS CE: Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. J Biol Chem 265: 8854-8862, 1990
30. BONNARDEL JA, DAVIS RA: In Hep-G2 cells, translocation, not degradation, determines the fate of the de novo synthesized apolipoprotein B. J Biol Chem 270:28892-28896, 1995
31. SATO R, IMANAKA T, TAKATSUKI A, TAKANO T: Degradation of newly synthesized apolipoprotein B-100 in a pre-Golgi compartment. J Biol Chem 265:11880-11884, 1990
32. DIXON JL, FURUKAWA S, GINSBERG HN: Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep-G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J Biol Chem 266:5080-5086, 1991
33. WANG CN, MCLEOD RS, YAO Z, BRINDLEY DN: Effect of dexamethasone on the synthesis, degradation and secretion of apolipoprotein B in cultured rat hepatocytes. Arterioscler Thromb Vasc Biol 15:1481-1491, 1995
34. HIRANO T, FURUKAWA M, KUROKAWA M, EBARA T, DIXON JL, NAGAMO S: Intracellular apoprotein B degradation is suppressed by decreased albumin concentration in Hep G2 cells. Kidney Int 47:421-431, 1995
35. ZHANG Z, SNIDERMAN AD, KALANT D, VU H, MONGE JC, TAO Y, CIANFLONE K: The role of amino acids in apo B-100 synthesis and catabolism in human Hep-G2 cells. J Biol Chem 268:26920-26926, 1993
36. DASHTI N: The effect of low density lipoproteins, cholesterol and 25-hydroxycholesterol on apolipoprotein B gene expression in Hep-G2 cells. J Biol Chem 267:7160-7169, 1992
37. CIANFLONE K, DAHAN S, MONGE JC, SNIDERMAN AD: Pathogenesis of carbohydrate-induced hypertriglyceridemia using HepG2 cells as a model system. Arteriosclerosis Thromb 12:271-277, 1992